Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

Feb 11, 2016, 17:10 ET from Reportlinker

NEW YORK, Feb. 11, 2016 /PRNewswire/ -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 393 pages. The personalized medicine (global & USA) market is presented as follows:

- By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies)
- By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) - By Therapy (Cancer, Cardiovascular, Infectious Disease)

Key Opinion Leaders that contributed to interview questions within the report include:

- Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group
- Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland
- Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC
- Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland
- Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine
- Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine
- David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine
- Deborah Phippard, PhD, Vice President, Research, Precision for Medicine
- Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine

A wealth of financial data & business strategy information is provided including:

- Company financials, sales & revenue figures
- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
- Business Model Strategies for Payers & Governments
- Private and Public Funding and Personalized Medicine Reimbursement
- Revisions to Current Payment Systems and intellectual property
- How to Gain Market Penetration in the EU
- Cost-effectiveness and Business Value of Personalized Medicine
- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
- Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
- Top fastest growing market segments and emerging opportunities
- Top pharmaceutical companies within the IPM by market share and revenue
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top personalized medicine pharmacos
- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)
- CE-marked Personalized Medicine/Diagnostic Tests
- FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

- 23andMe
- Abbott Laboratories
- Abbott Molecular Inc.
- Admera Health (GENEWIZ)
- Affymetrix
- Agendia
- Alere
- Amgen
- Astex Pharmaceuticals
- AstraZeneca
- Atossa Genetics
- Becton Dickenson
- bioMerieux
- BristolMyersSquibb
- Cancer Genetics
- Celera (Quest Diagnostics)
- Celldex Therapeutics
- Claritas Genomics
- CuraGen
- Danaher (Leica Biosystems)
- deCode Genetics (Amgen)
- Foundation Medicine
- EDP Biotech
- Eli Lilly
- ELDA BioTech
- Eisai
- Genelex
- GlaxoSmithKline
- Human Longevity Inc (Cypher Genomics)
- HalioDx
- Ikonisys
- Illumina
- InterGenetics
- Johnson & Johnson
- LabCorp
- Life Technologies
- Merck
- MDxHealth
- MolecularMD Corporation
- Monogram Biosciences
- Myriad
- Nodality
- Novartis MDx
- Orion Genomics
- Oxford BioTherapeutics
- NanoString Technologies
- Pfizer
- Qiagen
- Roche Molecular Diagnostics
- Sanofi
- SensiGen
- Siemens Healthcare Diagnostics
- Takeda
- Thermo Fisher Scientific
- Transgenomic
- Ventana (Roche)
- Vermillion (Ciphergen)
- Vertex Pharmaceuticals
What you will gain:

- An in-depth understanding of the global personalized medicine market and it's environment
- Current market facts, figures and product lines of key players in the industry
- Emerging trends in key markets such as the US, UK, Germany and France
- Knowledge of how the personalized medicine market will integrate into the global healthcare market
- Technical insights into new generation sequencing technologies and ultra-high throughput sequencing
- Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies
- FDA approved pharmacogenetic tests and recognized biomarkers
- Information on key government and regulatory policies
- Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the personalized medicine market such as:

- Lack of regulatory policy and legislation in the US and Europe
- Reimbursement schemes and payers concerns
- Transition of investigational diagnostic assays and therapeutics to clinical practice
- Direct to consumer (DTC) test kits and implications for the public

Who should read this report?

- Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine
- Industry professionals and business strategists will discover key information to propel their policies
- Investors will gain inside information to dominant players in the industry and future forecasts
- Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

This report will tell you if the companies mentioned are:

- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

This detailed report is supported with 360 figures and tables over 393 pages and profiles the main pharmacos in personalized medicine.

Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences
Post-sale complementary consultation with senior expert analyst is included
Use of tables and figures in your own reports and presentations is permitted
Each report provides straight-talking strategic analysis & sector intelligence
All reports are updated each quarter to give you the most up-to-date information

* Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker